Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 24 results for "Mk 5172"

THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORA...

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria april 22-26 Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria Stefan Zeuzem* 1, Reem Ghalib2, K. National AIDS Treatment Advocacy Project, 2 days ago

5 images for Mk 5172

MDLinx, 5 months ago
MDLinx, 5 months ago
Citybizlist, 6 months ago
Securities Technology Monitor, 6 months ago
Jutia Group, 6 months ago

VIDEO: C-SURFER: Patients with kidney disease, HCV achieve high rates of SVR

VIENNA — Howard Monsour Jr., MD, chief of hepatology, Houston Methodist Hospital, Texas, discussed results of the C-SURFER trial, where 99% of patients with advanced chronic kidney disease treated with grazoprevir and elbasvir for chronic ...
 Orthopedics Today1 day ago

C-SWIFT: 8 weeks of therapy may be possible with grazoprevir/elbasvir

VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV responded favorably to 8 weeks of treatment with a novel grazoprevir and elbasvir-based combination regimen, according to findings presented at the 2015 International Liver ...
 Orthopedics Today1 day ago C-EDGE: Grazoprevir/elbasvir regimen yields high SVR rates in patients with HCV  Orthopedics Today2 days ago C-SALT: Child-Pugh B patients responded to grazoprevir/elbasvir  Orthopedics Today2 days ago

EASL releases, outlines 2015 HCV recommendations

VIENNA — The goal of HCV therapy is to eradicate infection, according to Jean-Michel Pawlotsky, MD, PhD, Coordinator of the panel that published the 2015 EASL Recommendations on the Treatment of HCV. Pawlotsky, who is a professor at the ...
 Orthopedics Today2 days ago

Once-daily grazoprevir/elbasvir is effective in patients infected with chronic hepatitis C

249th ACS National Meeting & Exposition March 22-26, 2015 Denver, CO EurekAlert! provides embargoed and breaking science news you can't afford to miss. EurekAlert! offers a one-stop science news distribution service you can trust. EurekAlert! ...
 EurekAlert!2 days ago

Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals

Apr. 20, 2015 1:23 PM ET | About: Achillion Pharmaceuticals, Inc. (ACHN), Includes: GILD, MRK by: Steven Giardino Summary It is rare to have 3 or more pps moving catalysts on schedule from one company all within 8 months, but such is the case ...
 Seeking Alpha6 days ago

MERCK : Study Data from Merck & Company Update Knowledge of Hepatitis C Virus [Efficacy and safety of 8 weeks versus 12 weeks of treatment with...

Study Data from Merck & Company Update Knowledge of Hepatitis C Virus [Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus ...] ...
 4 Traders1 week ago Merck & Co. (MRK) Can't Catch a Break for Sugammadex, Faces Third FDA Rejection 3/17/2015  ClinicSpace1 month ago MERCK & CO., INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.  Pharmacy Choice1 month ago
Wheels.ca

2015 Jaguar XJL Review

Review Big cat offers plenty of creature comforts By admin April 13, 2015 The Pros and Cons WHATS BEST: Interior craftsmanship, wow factor from friends and colleagues WHATS WORST: The price but packages are reasonable for what you get ...
 Wheels.ca1 week ago
Motley Fool

3 Best Dividend Stocks in Healthcare

Quality matters. That's particularly true when buying stocks for their dividends. Some stocks claim high yields, but those dividends consume such a large percentage of the company's earnings that continued payout could be in jeopardy. The health ...
 Motley Fool2 weeks ago
Orthopedics Today

FDA grants new breakthrough therapy designations for grazoprevir/elbasvir

After rescinding breakthrough designation earlier this year, the FDA re-established two new designations for an oral combination tablet of grazoprevir/elbasvir for the treatment of chronic hepatitis C virus infection genotype 4 and genotype 1 with ...
 Orthopedics Today2 weeks ago Two HCV Treatments Lose Breakthrough Therapy Designation  Orthopedics Today1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less